Skip to main content
Premium Trial:

Request an Annual Quote

BioGX, Bosch Healthcare Solutions Partner to Develop Point-of-Care Infectious Disease Tests

NEW YORK – Molecular diagnostic reagent developer BioGX and Bosch Healthcare Solutions, a subsidiary of the Bosch Group, announced Wednesday a partnership to develop point-of-care infectious disease tests for Bosch's Vivalytic platform.

Birmingham, Alabama-based BioGX will develop, manufacture, and supply reagents for the Vivalytic cartridges, along with providing custom reagent manufacturing services for Vivalytic open system users. The companies said they will work together to seek regulatory approvals in different countries for in vitro diagnostic use.

Bosch's Vivalytic system uses cartridges preloaded with the necessary reagents, which allows for full automation and a faster turnaround time, according to the Waiblingen, Germany-based company. It can perform multiple kinds of tests, including endpoint PCR, quantitative real-time PCR, melt curve analysis, and microarray detection. The system is commercially available in the European Union.

Last month, Bosch said it was working with Randox Laboratories of Northern Ireland to develop a coronavirus test for the Vivalytic system.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.